Fig. 3: RapaBlock protects cells from mTOR inhibition by RapaLink-1 and rapamycin.
From: Brain-restricted mTOR inhibition with binary pharmacology
a,d, MCF7 cells were treated with a combination of RapaLink-1 and RapaBlock (a), or rapamycin and RapaBlock (d) for 4 h, then phosphorylation of mTOR substrates were analysed by immunoblotting. Results shown are representative of three independent experiments. GDPDH was used as the loading control. For gel source data, see Supplementary Fig. 1. b,e, Human PBMCs were stimulated with anti-CD3 and anti-CD28 in the presence of varying amounts of RapaLink-1 and RapaBlock (b) or rapamycin and RapaBlock (e), and cell proliferation was measured after 120 h (n = 3; data are presented as mean ± s.d.). c,f, Secretion of IL-2 in the culture supernatant of PBMCs stimulated with anti-CD3 and anti-CD28 and treated with Rapalink-1 (c) or rapamycin (f) was quantified by sandwich ELISA (n = 3; data are presented as mean ± s.d.).
